Table 1.
Baseline Characteristics of Anthropometric Measures, Pulmonary Variables, Inflammation Markers and 6-Min Walking Test in the Liraglutide Group and Placebo Group
| Group Characteristics | Liraglutide 3.0 mg (n = 20) | Placebo (n = 20) | p |
|---|---|---|---|
| Age (years) | 64.0 ± 8.4 | 65.3 ± 6.7 | NS |
| Male/female | 13/7 | 11/9 | NS |
| Bodyweight (kg) | 104.4 ± 13.6 | 102.5 ± 18.0 | NS |
| BMI (kg/m2) | 35.1 ± 3.7 | 36.6 ± 5.6 | NS |
| Waist: hip ratio | 1.07 ± 0.08 | 1.04 ± 0.09 | NS |
| FEV1 (L) | 1.8 ± 0.67 | 1.4 ± 0.67 | NS (p = 0.056) |
| FEV1 (%) | 62.8 ± 17.8 | 50.3 ± 20.2 | < 0.05 |
| FEV1/FVC (%) | 57.6 ± 9.4 | 48.2 ± 11.9 | <0.05 |
| FVC (L) | 3.16 ± 1.01 | 2.83 ± 0.99 | NS |
| FVC (%) | 86.4 ± 19.1 | 81.5 ± 19.3 | NS |
| TLC (%) | 106 ± 18 | 114 ± 22 | NS |
| DLCO (%) | 67.3 ± 25.1 | 52.2 ± 24.3 | NS |
| RV (%) | 147 ± 48 | 176 ± 53 | NS |
| MRC score | 2.05 ± 1.08 | 3 ± 1.06 | 0.01 |
| Eosinophils (10E9/L) | 0.19 ± 0.12 | 0.16 ± 0.11 | NS |
| Number of exacerbations the year before inclusion | 0.56 ± 0.70 | 0.77 ± 0.90 | NS |
| CCI | 3.26 ± 1.10 | 3.26 ± 1.05 | NS |
| CAT-score | 15.4 ± 6.1 | 17.8 ± 5.8 | NS |
| 6-min walking distance (m) | 419 ± 91 | 308 ± 138 | <0.01 |
| CRP (mg/L) | 5.3 ± 7.7 | 5.4 ± 4.7 | NS |
| IL-6 (pg/mL) | 5.3 ± 3.2 | 6.4 ± 3.6 | NS |
| MCP-1 (pg/mL) | 274 ± 95 | 281 ± 63 | NS |
Notes: Data are the mean ± SD. Sex is given in numbers. Significant changes between groups are given with p-values.
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; CRP, C reactive protein; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; CAT-score, COPD assessment test score; IL-6, Interleukin 6; MCP-1, Monocyte Chemoattractant Protein-1; TLC, total lung capacity; DLCO, diffusion capacity of the lung for carbon monoxide; RV, residual volume; NS, non-significant.